Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2391448
Max Phase: Preclinical
Molecular Formula: C13H13BrN4O2
Molecular Weight: 337.18
Molecule Type: Small molecule
Associated Items:
ID: ALA2391448
Max Phase: Preclinical
Molecular Formula: C13H13BrN4O2
Molecular Weight: 337.18
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1cc(N)c(=O)n(CC(=O)Nc2ccc(Br)cc2)n1
Standard InChI: InChI=1S/C13H13BrN4O2/c1-8-6-11(15)13(20)18(17-8)7-12(19)16-10-4-2-9(14)3-5-10/h2-6H,7,15H2,1H3,(H,16,19)
Standard InChI Key: WPYRTEPZXMIHCR-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 337.18 | Molecular Weight (Monoisotopic): 336.0222 | AlogP: 1.54 | #Rotatable Bonds: 3 |
Polar Surface Area: 90.01 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.69 | CX Basic pKa: | CX LogP: 0.72 | CX LogD: 0.72 |
Aromatic Rings: 2 | Heavy Atoms: 20 | QED Weighted: 0.89 | Np Likeness Score: -2.27 |
1. Giovannoni MP, Schepetkin IA, Cilibrizzi A, Crocetti L, Khlebnikov AI, Dahlgren C, Graziano A, Dal Piaz V, Kirpotina LN, Zerbinati S, Vergelli C, Quinn MT.. (2013) Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists., 64 [PMID:23685570] [10.1016/j.ejmech.2013.03.066] |
Source(1):